

Ref.: C.L.2.2025

The World Health Organization presents its compliments and has the honour to transmit, in accordance with Article 3 of the “Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances”,¹ the following list of proposed International Nonproprietary Names (prop. INN) which has been published by the World Health Organization in *WHO Drug Information*, Vol. 38, No. 4, 2024 on the WHO website at: WHO Drug Information, vol. 38, 4 [full issue]:

- p.INN list 132 from p. 1015 to 1307 (deadline for objecting and commenting is **13 June 2025**)

It would be appreciated if this communication could be forwarded to the appropriate patent and trade-mark office and to any other organization dealing with the introduction of nonproprietary names for pharmaceutical substances. Any comments that may be made, or notifications of a conflict between proposed names and existing proprietary rights, should be addressed to the INN Programme (innprogramme@who.int), World Health Organization, 1211 Geneva 27, within four months following the publication of the above-mentioned journal.

The selection of international nonproprietary names by the World Health Organization for use in all Member States presents many difficulties. It would therefore be appreciated if this were borne in mind when it is contemplated to exercise the right to raise objections.

Furthermore, the World Health Organization would be grateful if, in the interest of public health and pursuant to the procedure referred to in the first paragraph of this communication, the above-mentioned list of names could be granted protection in Member States during the period they are under consideration by the World Health Organization as international nonproprietary names.

GENEVA, 3 March 2025

¹ Annex to resolution EB15.R7, *Off. Rec. Wld Hlth Org.*, No. 60, pp. 3 and 55. This text was amended by resolution EB43.R9, *Off. Rec. Wld Hlth Org.*, No. 173, p. 10 and resolution EB115.R4, *Executive Board, 115th Session, Resolutions and Decisions (EB115/2005/REC/1)*, p. 2.